By vgreene, 8 March, 2019 If SLGT2-I not tolerated or contraindicated or if eGFR less than adequate, add GLP-1 RA w/ proven CVD benefit:1
By vgreene, 8 March, 2019 empagliflozin > canagliflozin (based on modestly stronger evidence, although both reduced HF and/or CKD progression in CV outcome trials)
By vgreene, 8 March, 2019 If pt 65 yo Consider coexisting conditions cognition functional status w care to avoid symptomatic hyperglycemia and minimize risk of acute hyperglycemia complications B 4
By vgreene, 8 March, 2019 Efficacy hypoglycemia risk 4 and wt concerns to consider when selecting antihyperglycemic tx
By vgreene, 8 March, 2019 SU (choose later gen, w/ lower hypoglycemia risk); glimepiride has shown similar CV safety to DPP4-I)